Centogene (NASDAQ:CNTG – Get Rating) was the recipient of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 35,000 shares, a growth of 87.2% from the July 15th total of 18,700 shares. Currently, 0.6% of the company's shares are short sold. Based on an average daily volume of 11,500 shares, the short-interest ratio is currently 3.0 days.
Institutional Trading of Centogene
A hedge fund recently raised its stake in Centogene stock. Acadian Asset Management LLC raised its holdings in shares of Centogene (NASDAQ:CNTG – Get Rating) by 16.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 70,725 shares of the company's stock after purchasing an additional 9,854 shares during the period. Acadian Asset Management LLC owned 0.36% of Centogene worth $366,000 at the end of the most recent quarter.
Get Centogene alerts:Centogene Price Performance
Centogene stock traded up $0.03 during mid-day trading on Thursday, reaching $1.43. 29,100 shares of the company were exchanged, compared to its average volume of 18,199. The business has a fifty day moving average of $2.11 and a 200 day moving average of $3.20. The company has a quick ratio of 2.41, a current ratio of 2.48 and a debt-to-equity ratio of 0.67. Centogene has a 12-month low of $1.34 and a 12-month high of $11.55.
Centogene (NASDAQ:CNTG – Get Rating) last posted its earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. The company had revenue of $11.59 million for the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. As a group, research analysts forecast that Centogene will post -1.72 EPS for the current fiscal year.Analyst Ratings Changes
Separately, SVB Leerink lowered their price target on Centogene from $10.00 to $6.00 and set an "outperform" rating for the company in a report on Monday, July 18th.
Centogene Company Profile
(Get Rating)
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
Read More
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 3 Stable Growth Stocks for Bumpy Times
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.